Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7382-7391

  Zou, Yiyu ^a   Fu, Hao ^b   Ghosh, Sukhen ^c   Farquhar, David ^c   Klostergaard, Jim ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SHENYANG MEDICAL COLLEGE   (China)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; CREMOPHOR; PACLITAXEL; POLYGLUTAMIC ACID PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG;

ACUTE TOXICITY; AEROSOL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FORMULATION; FLOW RATE; HUMAN; HUMAN CELL; HYDROPHILICITY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED ICR; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; POLYGLUTAMIC ACID; POLYMERS; PRODRUGS; TIME FACTORS;

EID: 8444230023     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0334     Document Type: Article

References (46)

1. DeVore RF, Johnson DH. Chemotherapy of small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors. Lung cancer. Principles and practice. Philadelphia: Lippincott-Raven; 1996. p. 825-35.
2. Bonomi P. Non-small cell lung cancer chemotherapy. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors. Lung cancer. Principles and practice. Philadelphia: Lippincott-Raven; 1996. p. 811-23.
3. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
4. Kris MG, Cohen E, Gralla RJ. An Analysis of 134 phase II trials in non-small-cell lung cancer. IV. Proceedings of World conference on Lung Cancer, Toronto, Canada; 1985. p39.
5. Murphy WK, Fossell AFV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst (Bethesda) 1993;85:384-88.
6. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
7. Cole SPC, Bhardwaj G, Gerlach JH. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash DC) 1992;258:1650-4.
8. Sugawara I, Yamada H, Nakamura H, et al. Preferential expression of the multidrug-resistance associated protein (MRP) in adenocarcinoma of the lung. Int J Cancer 1995;64:322-5.
9. Omelyanenko V, Kopeckova P, Gentry C, Kopecek J. Targetable HPMA copolymer-Adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release 1998;53:25-37.
10. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992;9:135-87.
11. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
12. Gilbert BE, Wyde PR, Wilson, SZ. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother 1992;36:146-71.
13. Knight V, Yu CP, Gilbert BE, Divine GW. Estimating dose of ribavirin aerosol according to age and other variables. J Infect Dis 1988;158:443-8.
14. Liebman JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumor cell lines. Cancer Chemother Pharmacol 1994;33:331-9.
15. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996;56:2112-5.
16. Thurston G, McLean JW, Rizen M, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Investig 1998;11:1401-13.
17. Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003;9:2335-41.
18. Bernsdorff C, Reszka R, Winter R. Interaction of the anticancer agent Taxol (paclitaxel) with phospholipid bilayers. J Biomed Mater Res 1999;46:141-9.
19. Perkins WR, Ahmad I, Li X, et al. Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int J Pharm 2000:27-39.
20. Ceruti M, Crosasso P, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J Control Release 2000;63:141-53.
21. Campbell RB, Balasubramanian SV, Straubinger RM. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J Pharm Sci 2001;90:1091-105.
22. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001;7:3258-62.
23. Treat J, Damjanov N, Huang C, Zrada S, Rahman A. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology 2001;15:44-8.
24. Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 1998;12:1035-40.
25. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)paclitaxel conjugate. Cancer Res 1998;58:2404-9.
26. Li C, Price JE, Milas L, et al. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 1999;5:891-7.
27. Li C, Ke S, Wu QP, et al. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 2000;6:2829-34.
28. Auzenne E, Donato NJ, Li C et al. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared to Taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res 2002;8:573-81.
29. Zou Y, Zong G, Ling YH, et al. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst (Bethesda) 1998;90:1130-7.
30. Kraus-Berthier L, Jan M, Guilbaud N, et al. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 2001;6:297-304.
31. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 1993;53:1743-6.
32. Nguyen DM, Lorang D, Chen GA, Stewart JH IV, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001;72:371-8.
33. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003:1089-105.
34. Zou Y, Wu QP, Tansey W, et al. Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice. Int J Oncol 2001;18:331-6.
35. Huisman C, Ferreira CG, Broker LE, et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCl-H460. Clin Cancer Res 2002;8:596-606.
36. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6:4932-8.
37. Nagamachi Y, Tani M, Shimizu K, Tsuda H, Niitsu Y, Yokota J. Orthotopic growth and metastasis of human non-small cell lung carcinoma cell injected into the pleural cavity of nude mice. Cancer Lett 1998;127:203-9.
38. Miyoshi T, Kondo K, Ishikura H, Kinoshita H, Matsumori Y, Monden Y. SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res 2000;20:161-3.
39. Yamaura T, Murakami K, Doki Y, et al. Solitary lung tumors and their spontaneous metastasis in athymic nude mice orthotopically implanted with human non-small cell lung cancer. Neoplasia 2000;2:315-24.
40. Boehle AS, Sipos B, Kliche U, Kalthoff H, Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 2001;71:1657-65.
41. Boehle AS, Kurdow R, Schulze M, et al. Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer 2001;94:420-8.
42. Ishikura H, Kondo K, Miyoshi T, et al. Suppression of mediastinal metastasis by uracil-tegafur of cis-diamminedichloroplatinum(II) using a lymphogenous metastatic model in a human lung cancer cell line. Clin Cancer Res 2001;7:4202-8.
43. Fujino H, Kondo K, Miyoshi T, et al. Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically-resected lung cancer tissues. Oncol Rep 2003;10:1709-15.
44. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994;1:5-13.
45. Vertrees RA, Deyo DJ, Quast M, Lightfoot KM, Boor PJ, Zwischenberger JB. Development of a human to murine orthotopic xenotransplanted lung cancer model. J Investig Surg 2000;13:349-58.
46. Phase II clinical trial of XYOTAX in non-small cell lung cancer to continue. Expert Rev Anticancer Ther 2002;2:244-5.